Tonix Pharmaceuticals (NASDAQ:TNXP) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report released on Saturday. The brokerage issued a hold rating on the stock.

Tonix Pharmaceuticals Price Performance

NASDAQ:TNXP opened at $0.41 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The stock has a market cap of $77.02 million, a P/E ratio of -0.01 and a beta of 2.02. The company has a fifty day moving average price of $0.28 and a 200 day moving average price of $0.28. Tonix Pharmaceuticals has a one year low of $0.12 and a one year high of $12.48.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $1.80. The business had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Analysts anticipate that Tonix Pharmaceuticals will post -17.63 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.